title: The challenges of managing and treating Guillain-Barré syndrome during the acute phase.
abstract: Guillain-Barré syndrome (GBS) is a randomly acquired inflammatory disease that affects approximately 2 persons in 100,000 annually. There have been no discriminating risk factors identified including age, sex, or race. The syndrome results in the demyelination of peripheral nerves, which leads to progressive motor weakness and paralysis. The critical care nurse should gain from this article an overview of Guillain-Barré syndrome during the acute phase. Included is the pathophysiology of the syndrome, clinical presentation, acute phase nursing assessment and management, and currently available treatment options.
authors.affiliation: Gastroenterology Associates, Spartanburg, SC, USA.
authors.forename: Stephanie B
authors.initials: SB
authors.lastname: Atkinson
authors.forename: Rebecca Lamb
authors.initials: RL
authors.lastname: Carr
authors.forename: Patricia
authors.initials: P
authors.lastname: Maybee
authors.forename: Donna
authors.initials: D
authors.lastname: Haynes
mesh_terms: D000208:Acute Disease; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D015984:Causality; D002555:Cerebrospinal Fluid; D003422:Critical Care / Q000379:methods*; D018450:Disease Progression; D005374:Filtration; D020275:Guillain-Barre Syndrome / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology / Q000628:therapy*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D008991:Monitoring, Physiologic / Q000451:nursing; D024802:Nurse's Role; D009730:Nursing Assessment; D018579:Patient Selection; D010951:Plasma Exchange; D020127:Recovery of Function; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D016756:Immunoglobulins, Intravenous